Related Experiment Video

Updated: Aug 1, 2026

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
10:44

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

CYP2D6 genotyping in patients on psychoactive drug therapy

E Topić1, M Stefanović, A M Ivanisević

  • 1Clinical Institute of Chemistry, School of Medicine, University of Zagreb and Sestre milosrdnice University Hospital, Zagreb, Croatia. elizabeta.topic@zg.tel.hr

Clinical Chemistry and Laboratory Medicine
|November 30, 2000
PubMed

Insights

CYP2D6 gene variations impact how the body processes psychoactive drugs. This study found a link between specific CYP2D6 mutations and schizophrenia, as well as drug side effects in these patients.

Area of Science:

  • Pharmacogenomics
  • Clinical Genetics
  • Neuroscience

Background:

  • The cytochrome P450 2D6 (CYP2D6) enzyme is crucial for metabolizing numerous psychoactive medications.
  • Genetic variations, specifically null alleles (*3, *4, *5, *6, *7, *8), can lead to inactive CYP2D6 enzymes, resulting in poor or intermediate metabolizer phenotypes.
  • Understanding CYP2D6 allele prevalence is important for personalized medicine in psychiatric treatment.

Purpose of the Study:

  • To investigate the prevalence of CYP2D6 null alleles in patients with depression and schizophrenia compared to healthy controls.
  • To determine the association between CYP2D6 gene polymorphism and the risk of side effects in schizophrenic patients on long-term psychoactive drug therapy.

Main Methods:

  • Multiplex allele-specific PCR was employed to analyze CYP2D6 genotypes.
  • The study included 49 patients with depression, 86 with schizophrenia, and 145 healthy individuals.
  • Genotype and phenotype distributions were compared across groups, and odds ratios were calculated to assess associations.

Main Results:

  • No significant differences in CYP2D6 allele prevalence, genotype, or phenotype distribution were found between the depression group and controls.
  • Schizophrenic patients showed a significant difference in allele frequency (p=0.002), genotype distribution (p=0.016), and phenotype prevalence (p=0.018) compared to controls.
  • The CYP2D6*4 allele was significantly associated with schizophrenia (OR=2.542) and poor metabolizer phenotype (OR=5.020).
  • Significant associations were observed between CYP2D6 variations (CYP2D6*4, CYP2D6*6, poor metabolizer phenotype) and the occurrence of side effects in schizophrenic patients (p<0.05).

Conclusions:

  • CYP2D6 genotyping may be a valuable tool for predicting the risk of psychoactive drug side effects in schizophrenic patients.
  • The findings suggest a genetic predisposition related to drug metabolism influences drug efficacy and safety in schizophrenia.
  • Further research is warranted to explore the clinical utility of CYP2D6 genotyping in optimizing psychiatric pharmacotherapy.

More Related Videos

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry10:17

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry

Published on: April 23, 2019

Related Concept Videos

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...